At a glance
A short peptide discussed in enzyme and chromatin research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes cell and animal findings. Enzyme inhibition and changes in gene markers do not alone establish improved organ function in humans.[1][4][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Livagen.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (500 mcg) | 7.5 units (0.075 mL) |
| Weeks 3–4 | 1.0 mg (1000 mcg) | 15 units (0.15 mL) |
| Weeks 5–6 | 1.5 mg (1500 mcg) | 22.5 units (0.225 mL) |
| Weeks 7–12 | 2.0 mg (2000 mcg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to yield measurable volumes on standard insulin syringes. For ≤10-unit (≤0.10 mL) administrations (e.g., the initial 7.5-unit dose), consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support cellular homeostasis and regenerative processes in aging tissues[3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 0.5–2.0 mg daily with gradual titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 0.5 mg daily; increase by ~0.5 mg every 1–2 weeks as tolerated.
- Target: 1.5–2.0 mg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7].
- Clean the vial stopper and skin with alcohol; allow to dry[6].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6].
- Dispose of used syringes immediately in a sharps container[5].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Livagen, 20 mg each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 10 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
PubMed — Functional morphology of an organotypic liver culture exposed to the peptide Livagen (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
CDC — Preventing Unsafe Injection Practices (clinical safety and sharps disposal) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
MedlinePlus — Subcutaneous (SQ) injections: technique, site rotation, and skin preparation (opens in a new tab)medlineplus.gov
Back to overview ↑ - 07
Research publication
PMC — Subcutaneous Drug Injection Review: pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.